

Inflammatory Bowel Disease Market Report 2032: Epidemiology Data, Therapies, Latest FDA, EMA, Approvals by DelveInsight

As per DelveInsight's analysis, the inflammatory bowel disease market is anticipated to witness growth at a considerable CAGR.

LAS VEGAS, NEVADA, UNITED STATES, April 1, 2024 /EINPresswire.com/ -- DelveInsight's "Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Inflammatory Bowel Disease Market Forecast](#)

Some of the key facts of the Inflammatory Bowel Disease Market Report:

The Inflammatory Bowel Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

Key Inflammatory Bowel Disease Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others

Key Inflammatory Bowel Disease Therapies: Entyvio (Vedolizumab), Stelara (Ustekinumab), Etrolizumab (RG7413), Skyrizi (Risankizumab/BI 655066/ABBV-066), and others

The market size of IBD in the APAC region is expected to reach USD 3,672 million by 2030. In 2021, China accounted for the highest market size of IBD, compared to the other major markets, i.e., USD 748 million.

Among the other APAC countries apart from China, Japan had the highest market size with USD 709 million in 2021, while South Korea had the lowest market size of IBD with USD 75 million in 2021.

Of the emerging therapies Skyrizi, Etrolizumab, Jyselica and others are expected to enter the treatment market, during the forecast period. Alofisel is recently approved in Japan in 2021 and

is expected to enter the other APAC countries.

The expected launch of potential therapies shall increase the market size in the coming years, assisted by an increase in the prevalent population of IBD during the forecast period.

Total prevalent population of IBD in the APAC regions was 3,907,112 cases in 2021 which is expected to increase during the study period.

Japan accounted for third highest (205,859) cases of IBD, compared to other Asian regions (China (1,917,172 cases), India (1,566,102 cases), Australia (168,539 cases), and South Korea (49,440 cases)) in 2021.

Males accounted for a higher number of IBD cases in the APAC region in 2021. There were 1,708,495 cases and 1,293,034 cases of IBD in males and females respectively in 2021.

The maximum number of prevalent IBD cases in the APAC region were found in the age group 40+ years, followed by those aged 20–39 years. As per estimates, the age group of 40+ years contributed to 1,549,013 cases in 2021, which is anticipated to increase throughout the study period 2018–2030.

IBD patients are further classified based on the severity of the disease. Patients with mild, and moderate to severe accounts for approximately 1,014,670 cases, and 1,986,860 cases respectively in 2021.

The Inflammatory Bowel Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.

Inflammatory Bowel Disease Overview

The digestive system, one of the body's largest organ systems, begins at the mouth, where food enters, and ends at the anus, where waste is expelled. Like other bodily systems, it can be affected by various ailments, including inflammatory bowel disease (IBD). IBD encompasses disorders characterized by chronic inflammation of different parts of the digestive tract, including the mouth, esophagus, stomach, small intestine, and large intestine. Its primary functions include breaking down food, absorbing nutrients, and eliminating waste. Inflammation disrupts these functions, leading to difficulties in nutrient absorption. IBD is a long-lasting or recurrent condition, comprising two main types: Crohn's disease (CD) and Ulcerative colitis (UC), which share similarities but also exhibit important distinctions.

Inflammatory Bowel Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key

opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Inflammatory Bowel Disease Epidemiology Segmentation:

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Inflammatory Bowel Disease

Prevalent Cases of Inflammatory Bowel Disease by severity

Gender-specific Prevalence of Inflammatory Bowel Disease

Diagnosed Cases of Episodic and Chronic Inflammatory Bowel Disease

Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ [Inflammatory Bowel Disease Epidemiology Forecast](#)

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammatory Bowel Disease Therapies

Entyvio (Vedolizumab)

Stelara (Ustekinumab)

Etrolizumab (RG7413)

Skyrizi (Risankizumab/BI 655066/ABBV-066)

Inflammatory Bowel Disease Key Companies

Takeda Pharmaceutical

Janssen Pharmaceuticals

Hoffmann-La Roche
Genentech
AbbVie
Boehringer Ingelheim
Gilead Sciences
Arena Pharmaceuticals
Eli Lilly
AstraZeneca

Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ [Inflammatory Bowel Disease Treatment Landscape](#)

Inflammatory Bowel Disease Market Outlook

Inflammatory Bowel Disease (IBD) encompasses gastrointestinal conditions such as ulcerative colitis (UC) and Crohn's Disease (CD), characterized by a relapsing-remitting course that can affect individuals of any age. The current treatment options for IBD include traditional therapies like aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors, anti-TNF agents, anti-adhesion molecules, as well as newer options such as small molecules targeting the JAK pathways, anti IL12/23, and cell therapies.

Various types of immunomodulators, each with distinct mechanisms of action, are utilized for treating IBD patients in the APAC market. TNF inhibitors have long been pivotal in altering the treatment landscape for UC and CD. However, their usage is restricted due to systemic side effects, including immunosuppression and cardiotoxicity, particularly in elderly patients, even among those who respond to TNF therapy. In 2020, Humira (adalimumab) emerged as a top-selling anti-TNF therapy for managing several conditions, including CD and UC. It obtained approval in Japan for treating Crohn's Disease (CD) in 2010. Amgevita, a biosimilar of Humira, received approval from the Australian Therapeutic Goods Administration in 2017 for various conditions, including rheumatoid arthritis (RA), juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, CD in adults and children (≥ 6 years), ulcerative colitis, psoriasis in adults and children, hidradenitis suppurativa, and uveitis. Another anti-TNF therapy, infliximab, gained approval from Japanese regulators in 2002 for CD treatment, later extended to UC as well. In 2018, the Chinese guidelines incorporated infliximab for treating UC patients. Moreover, in 2018, the Australian regulatory body approved the infliximab biosimilar Inflectra for managing adult and pediatric Crohn's disease, refractory fistulising CD, and adult and pediatric UC.

Scope of the Inflammatory Bowel Disease Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Inflammatory Bowel Disease Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others

Key Inflammatory Bowel Disease Therapies: Entyvio (Vedolizumab), Stelara (Ustekinumab), Etrolizumab (RG7413), Skyrizi (Risankizumab/BI 655066/ABBV-066), and others

Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies

Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Inflammatory Bowel Disease Unmet Needs, KOL's views, Analyst's views, Inflammatory Bowel Disease Market Access and Reimbursement

Table of Contents

1. Inflammatory Bowel Disease Market Report Introduction
2. Executive Summary for Inflammatory Bowel Disease
3. SWOT analysis of Inflammatory Bowel Disease
4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance
5. Inflammatory Bowel Disease Market Overview at a Glance
6. Inflammatory Bowel Disease Disease Background and Overview
7. Inflammatory Bowel Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Inflammatory Bowel Disease
9. Inflammatory Bowel Disease Current Treatment and Medical Practices
10. Inflammatory Bowel Disease Unmet Needs
11. Inflammatory Bowel Disease Emerging Therapies
12. Inflammatory Bowel Disease Market Outlook
13. Country-Wise Inflammatory Bowel Disease Market Analysis (2019–2032)
14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies
15. Inflammatory Bowel Disease Market Drivers
16. Inflammatory Bowel Disease Market Barriers
17. Inflammatory Bowel Disease Appendix
18. Inflammatory Bowel Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Inflammatory Bowel Disease Pipeline

"Inflammatory Bowel Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Inflammatory Bowel Disease market. A detailed picture of the Inflammatory Bowel Disease pipeline landscape is provided, which includes the disease overview and Inflammatory Bowel Disease treatment guidelines.

Inflammatory Bowel Disease Epidemiology

DelveInsight's 'Inflammatory Bowel Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Inflammatory Bowel Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: <https://www.delveinsight.com/consulting>

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/700296617>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.